Fair Value |
6. Fair Value
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is based on the assumptions market participants would use when pricing an asset or liability and follows a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. An instrument’s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
All aspects of nonperformance risk, including the Company’s own credit standing, are considered when measuring the fair value of a liability.
Following is a description of the three levels of the fair value hierarchy:
Level 1 Inputs: Quoted prices for identical instruments in active markets.
Level 2 Inputs: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
Level 3 Inputs: Instruments with unobservable inputs that are significant to the fair value measurement.
The Company classifies assets and liabilities in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2023 and 2022. Refer to Note 2 - Summary of Significant Accounting Policies for additional information on our accounting policies related to assets and liabilities that are measured at fair value.
Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and the details of the valuation models, key inputs to those models, and significant assumptions utilized. Within the assumption tables presented, not meaningful (“NM”) refers to a range of inputs that is too broad to provide meaningful information to the user or to an input that has no range and consists of a single data point.
|
|
|
|
|
|
|
|
|
|
|
|
Instrument |
Valuation techniques |
Classification of Fair Value Hierarchy |
Assets |
Loans held for investment, subject to HMBS related obligations(1)
|
|
HECM loans - securitized into Ginnie Mae HMBS |
These loans are valued utilizing a present value methodology that discounts estimated projected cash flows over the life of the loan portfolio using conditional prepayment rate (“CPR”), loss frequency, loss severity, borrower draw, and discount rate assumptions. |
Level 3 |
Loans held for investment, subject to nonrecourse debt(1)
|
|
HECM buyouts - securitized (nonperforming) |
These loans are valued utilizing a present value methodology that discounts estimated projected cash flows over the life of the portfolio using CPR, loss frequency, loss severity, and discount rate assumptions. |
Level 3 |
|
HECM buyouts - securitized (performing) |
These loans are valued utilizing a present value methodology that discounts estimated projected cash flows over the life of the portfolio using weighted average remaining life (“WAL”), CPR, loss severity, and discount rate assumptions. |
Level 3 |
|
Non-agency reverse mortgage loans - securitized |
These loans are valued utilizing a present value methodology that discounts estimated projected cash flows over the life of the portfolio using WAL, loan-to-value (“LTV”), CPR, loss severity, home price appreciation (“HPA”), and discount rate assumptions. |
Level 3 |
|
Commercial mortgage loans - securitized |
This product is valued using a discounted cash flow model utilizing a single monthly mortality prepayment rate (“SMM”), discount rate, and loss rate assumptions. |
Level 3 |
(1) The Company aggregates loan portfolios based on the underlying securitization trust and values these loans using these aggregated pools. The range of inputs provided is based on the range of inputs utilized for each securitization trust.
|
|
|
|
|
|
|
|
|
|
|
|
|
Loans held for investment |
|
Inventory buyouts |
The fair value of repurchased loans is based on expected cash proceeds of the liquidation of the underlying properties and expected claim proceeds from HUD. The primary assumptions utilized in valuing nonperforming repurchased loans include CPR, loss frequency, loss severity, and discount rate.
Termination proceeds are adjusted for expected loss frequencies and severities to arrive at net proceeds that will be provided upon final resolution, including assignments to FHA. Historical experience is utilized to estimate the loss rates resulting from scenarios where FHA insurance proceeds are not expected to cover all principal and interest outstanding and, as servicer, the Company is exposed to losses upon resolution of the loan.
|
Level 3 |
|
Non-agency reverse mortgage loans |
The fair value of non-agency reverse mortgage loans is based on values for investments with similar investment grade ratings and the value the Company would expect to receive if the whole loans were sold to an investor.
The Company values non-agency reverse mortgage loans utilizing a present value methodology that discounts estimated projected cash flows over the life of the loan portfolio. The primary assumptions utilized in valuing the loans include WAL, LTV, CPR, loss severity, HPA, and discount rate.
|
Level 3 |
|
Commercial mortgage loans |
This product is valued using a discounted cash flow (“DCF”) model with SMM, discount rate, and constant default rate (“CDR”) assumptions. |
Level 3 |
Loans held for sale |
|
Residential mortgage loans |
This includes all mortgage loans that can be sold to the agencies, which are valued predominantly by published forward agency prices. This will also include all non-agency loans where recently negotiated market prices for the loan pool exist with a counterparty (which approximates fair value), or quoted market prices for similar loans are available. |
Level 2 |
|
|
|
|
|
Commercial mortgage loans |
This product is valued using a DCF model utilizing CPR, discount rate, and CDR assumptions. |
Level 3 |
Mortgage Servicing Rights |
|
MSR |
The Company valued MSR internally through a DCF analysis and calculated using a pricing model. This pricing model is based on the objective characteristics of the portfolio (loan amount, note rate, etc.) and commonly used industry assumptions such as discount rate and weighted average CPR. |
Level 3 |
Derivative assets/liabilities |
|
LPCs, forward MBS, and TBAs |
LPCs are valued based on current market prices for HMBS.
Forward MBS and TBAs are valued using forward dealer marks from the Company’s approved counterparties, forward prices with dealers in such securities, or internally-developed or third-party models utilizing observable market inputs.
|
Level 2 |
|
Interest rate swaps and futures contracts |
This product is valued using quoted market prices. |
Level 1 |
Other assets |
|
|
|
|
|
Retained bonds |
Management obtains third-party valuations to assess the reasonableness of the fair value calculations provided by the internal valuation model. The primary assumptions utilized include WAL and discount rate. |
Level 3 |
|
|
|
|
|
Purchase commitments - reverse mortgage loans |
Purchase commitments are valued based on the value of the underlying loan. These loans are valued based on an expected margin on sale of 3.00% as of December 31, 2022. There were not any reverse mortgage loan purchase commitments as of December 31, 2023. |
Level 3 |
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
HMBS related obligations |
|
HMBS related obligations |
The estimated fair value is based on the net present value of projected cash flows over the estimated life of the liability. The estimated fair value of the HMBS related obligations also includes the consideration required by a market participant to transfer the HECM and HMBS servicing obligations, including exposure resulting from shortfalls in FHA insurance proceeds as well as assumptions that it believes a market participant would consider in valuing the liability, including, but not limited to, assumptions for repayment, costs to transfer servicing obligations, shortfalls in FHA insurance proceeds, and discount rates. The significant unobservable inputs used in the measurement include CPR and discount rates. |
Level 3 |
Nonrecourse debt |
|
Nonrecourse reverse mortgage loan financing liability |
The estimated fair value is based on the net present value of projected cash flows over the estimated life of the liability. The significant unobservable inputs used in the measurement include WAL, CPR, and discount rates. |
Level 3 |
|
Nonrecourse commercial loan financing liability |
The estimated fair value is based on the net present value of projected cash flows over the estimated life of the liability.
The primary assumptions utilized include WAL, weighted average SMM, and discount rates. The Company estimates prepayment speeds giving consideration that the Company may in the future transfer additional loans to the trust, subject to the availability of funds provided for within the trust.
|
Level 3 |
|
Nonrecourse MSR financing liability |
Consistent with the underlying MSR, fair value is derived through a DCF analysis and calculated using a pricing model. This pricing model is based on the objective characteristics of the portfolio (loan amount, note rate, etc.) and commonly used industry assumptions including weighted average CPR and discount rate. |
Level 3 |
Deferred purchase price liabilities |
|
Deferred purchase price liabilities |
These liabilities are measured based on the estimated amount of indemnified claims associated with the AAG Transaction and the closing market price of the Company’s publicly-traded stock on the applicable date of the Consolidated Statements of Financial Condition. Refer to Note 3 - Acquisitions for additional information. |
Level 3 |
|
TRA obligation |
The fair value is derived through the use of a DCF model. The significant unobservable assumptions used in the DCF include the ability to utilize tax attributes based on current tax forecasts, a constant U.S. federal income tax rate, and a discount rate. |
Level 3 |
Warrant liability |
|
Warrants |
The warrants are publicly-traded and are valued based on the closing market price of the applicable date of the Consolidated Statements of Financial Condition. |
Level 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
December 31, 2022 |
Instrument / Unobservable Inputs |
|
Range |
|
Weighted Average |
|
Range |
|
Weighted Average |
Assets |
Loans held for investment, subject to HMBS related obligations |
|
CPR |
|
NM |
|
20.1
|
% |
|
NM |
|
21.9 |
% |
|
Loss frequency |
|
NM |
|
4.5
|
% |
|
NM |
|
4.1 |
% |
|
Loss severity |
|
3.4% - 12.9% |
|
3.5
|
% |
|
2.4% - 12.1% |
|
2.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
December 31, 2022 |
Instrument / Unobservable Inputs |
|
Range |
|
Weighted Average |
|
Range |
|
Weighted Average |
|
Discount rate |
|
NM |
|
5.0
|
% |
|
NM |
|
5.0 |
% |
|
Average draw rate |
|
NM |
|
1.1
|
% |
|
NM |
|
1.1 |
% |
Loans held for investment, subject to nonrecourse debt: |
|
HECM buyouts - securitized (nonperforming) |
|
|
|
|
|
CPR |
|
NM |
|
39.8
|
% |
|
NM |
|
39.2 |
% |
|
Loss frequency |
|
23.1% - 100.0% |
|
51.0
|
% |
|
23.1% - 100% |
|
51.7 |
% |
|
Loss severity |
|
3.4% - 12.8% |
|
6.4
|
% |
|
2.4% - 12.1% |
|
5.2 |
% |
|
Discount rate |
|
NM |
|
8.6
|
% |
|
NM |
|
8.7 |
% |
|
HECM buyouts - securitized (performing) |
|
|
|
|
|
WAL (in years) |
|
NM |
|
7.4 |
|
NM |
|
8.0 |
|
CPR |
|
NM |
|
15.1
|
% |
|
NM |
|
15.2 |
% |
|
Loss severity |
|
3.4% - 12.8% |
|
6.9
|
% |
|
2.4% - 12.1% |
|
4.8 |
% |
|
Discount rate |
|
NM |
|
8.2
|
% |
|
NM |
|
8.2 |
% |
|
Non-agency reverse mortgage loans - securitized |
|
|
|
WAL (in years) |
|
NM |
|
9.7 |
|
NM |
|
9.7 |
|
LTV |
|
0.0% - 79.6% |
|
45.9
|
% |
|
0.0% - 74.7% |
|
43.1 |
% |
|
CPR |
|
NM |
|
14.7
|
% |
|
NM |
|
14.3 |
% |
|
Loss severity |
|
NM |
|
10.0
|
% |
|
NM |
|
10.0 |
% |
|
HPA |
|
(9.8)% - 7.6% |
|
3.3
|
% |
|
(10.1)% - 7.3% |
|
3.8 |
% |
|
Discount rate |
|
NM |
|
6.9
|
% |
|
NM |
|
7.1 |
% |
|
Commercial mortgage loans - securitized |
|
|
|
|
|
|
|
SMM |
|
NM |
|
10.7
|
% |
|
NM |
|
11.2 |
% |
|
Discount rate |
|
NM |
|
16.5
|
% |
|
NM |
|
17.5 |
% |
|
Loss rate |
|
NM |
|
1.0
|
% |
|
NM |
|
0.5 |
% |
Loans held for investment: |
|
Inventory buyouts |
|
|
|
|
|
|
|
|
|
CPR |
|
NM |
|
41.5
|
% |
|
NM |
|
41.3 |
% |
|
Loss frequency |
|
NM |
|
48.2
|
% |
|
NM |
|
47.6 |
% |
|
Loss severity |
|
3.4% - 12.8% |
|
5.1
|
% |
|
2.4% - 12.1% |
|
5.6 |
% |
|
Discount rate |
|
NM |
|
8.6
|
% |
|
NM |
|
8.7 |
% |
|
Non-agency reverse mortgage loans |
|
|
|
|
|
|
|
|
|
WAL (in years) |
|
NM |
|
12.1 |
|
NM |
|
12.0 |
|
LTV |
|
3.9% - 53.8% |
|
33.8
|
% |
|
0.1% - 67.9% |
|
36.4 |
% |
|
CPR |
|
NM |
|
14.4
|
% |
|
NM |
|
13.8 |
% |
|
Loss severity |
|
NM |
|
10.0
|
% |
|
NM |
|
10.0 |
% |
|
HPA |
|
(9.8)% - 7.6% |
|
3.1
|
% |
|
(10.1)% - 7.3% |
|
3.6 |
% |
|
Discount rate |
|
NM |
|
6.9
|
% |
|
NM |
|
7.1 |
% |
|
Commercial mortgage loans |
|
|
|
|
|
|
|
SMM |
|
NM |
|
73.6
|
% |
|
NM |
|
9.6 |
% |
|
CDR |
|
NM |
|
25.6
|
% |
|
NM |
|
1.0 |
% |
|
Discount rate |
|
9.6% - 20.0% |
|
13.2
|
% |
|
9.7% - 25.8% |
|
16.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
December 31, 2022 |
Instrument / Unobservable Inputs |
|
Range |
|
Weighted Average |
|
Range |
|
Weighted Average |
Loans held for sale: |
|
Commercial mortgage loans |
|
|
|
|
|
|
|
|
|
CPR |
|
N/A |
|
N/A |
|
NM |
|
19.2 |
% |
|
Discount rate |
|
N/A |
|
N/A |
|
8.3% - 10.9% |
|
9.4 |
% |
|
CDR |
|
N/A |
|
N/A |
|
NM |
|
1.0 |
% |
Mortgage Servicing Rights |
|
Weighted average CPR |
|
NM |
|
NM |
|
1.0% - 8.5% |
|
6.4 |
% |
|
Discount rate |
|
NM |
|
NM |
|
NM |
|
10.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets: |
|
Retained bonds |
|
|
|
|
|
|
|
|
|
WAL (in years) |
|
2.3 - 23.4 |
|
4.9 |
|
2.4 - 24.1 |
|
4.9 |
|
Discount rate |
|
(31.2)% - 12.3% |
|
6.7
|
% |
|
(16.8)% - 12.2% |
|
6.9 |
% |
|
|
|
|
|
|
|
|
|
|
Liabilities |
HMBS related obligations |
|
CPR |
|
NM |
|
23.8
|
% |
|
NM |
|
21.8 |
% |
|
Discount rate |
|
NM |
|
5.0
|
% |
|
NM |
|
5.0 |
% |
Nonrecourse debt: |
|
Reverse mortgage loans: |
|
|
|
|
|
|
|
|
|
Performing/Nonperforming HECM securitizations |
|
|
|
|
|
|
|
WAL (in years) |
|
NM |
|
0.9 |
|
1.5 - 1.6 |
|
1.6 |
|
CPR |
|
21.5% - 22.3% |
|
21.9
|
% |
|
19.9% - 22.2% |
|
21.1 |
% |
|
Discount rate |
|
NM |
|
10.0
|
% |
|
NM |
|
8.6 |
% |
|
Securitized non-agency reverse |
|
|
|
|
|
|
|
|
|
WAL (in years) |
|
0.8 - 11.2 |
|
4.5 |
|
0.2 - 11.7 |
|
6.4 |
|
CPR |
|
10.6% - 22.3% |
|
14.7
|
% |
|
8.3% - 46.1% |
|
16.5 |
% |
|
Discount rate |
|
NM |
|
7.0
|
% |
|
NM |
|
7.2 |
% |
|
Nonrecourse commercial loan financing liability |
|
WAL (in months) |
|
NM |
|
1.8 |
|
NM |
|
4.3 |
|
Weighted average SMM |
|
NM |
|
33.3
|
% |
|
NM |
|
15.3 |
% |
|
Discount rate |
|
NM |
|
9.1
|
% |
|
NM |
|
14.5 |
% |
|
Nonrecourse MSR financing liability |
|
|
|
|
|
|
|
|
|
Weighted average CPR |
|
N/A |
|
N/A |
|
0.8% - 9.2% |
|
5.1 |
% |
|
Discount rate |
|
N/A |
|
N/A |
|
10.0% - 12.0% |
|
10.2 |
% |
Deferred purchase price liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TRA obligation |
|
|
|
|
|
|
|
|
|
Discount rate |
|
NM |
|
33.0
|
% |
|
NM |
|
48.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
Fair Value of Assets and Liabilities
The following table provides a summary of the recognized assets and liabilities that are measured at fair value on a recurring basis (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
Total Fair Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets |
|
|
|
|
|
|
|
Loans held for investment, subject to HMBS related obligations |
$ |
17,548,763
|
|
|
$ |
—
|
|
|
$ |
—
|
|
|
$ |
17,548,763
|
|
Loans held for investment, subject to nonrecourse debt: |
|
|
|
|
|
|
|
Reverse mortgage loans |
8,138,403
|
|
|
—
|
|
|
—
|
|
|
8,138,403
|
|
Commercial mortgage loans |
133,990
|
|
|
—
|
|
|
—
|
|
|
133,990
|
|
Loans held for investment: |
|
|
|
|
|
|
|
Reverse mortgage loans |
574,271
|
|
|
—
|
|
|
—
|
|
|
574,271
|
|
Commercial mortgage loans |
957
|
|
|
—
|
|
|
—
|
|
|
957
|
|
|
|
|
|
|
|
|
|
Loans held for sale: |
|
|
|
|
|
|
|
Residential mortgage loans |
4,246
|
|
|
—
|
|
|
4,246
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MSR |
6,436
|
|
|
—
|
|
|
—
|
|
|
6,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retained bonds |
44,297
|
|
|
—
|
|
|
—
|
|
|
44,297
|
|
LPCs |
630
|
|
|
—
|
|
|
630
|
|
|
—
|
|
Total assets |
$ |
26,451,993
|
|
|
$ |
—
|
|
|
$ |
4,876
|
|
|
$ |
26,447,117
|
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
HMBS related obligations |
$ |
17,353,720
|
|
|
$ |
—
|
|
|
$ |
—
|
|
|
$ |
17,353,720
|
|
Nonrecourse debt: |
|
|
|
|
|
|
|
Nonrecourse debt in consolidated VIE trusts and reverse loan financing liability |
7,876,932
|
|
|
—
|
|
|
—
|
|
|
7,876,932
|
|
Nonrecourse commercial loan financing liability |
27,268
|
|
|
—
|
|
|
—
|
|
|
27,268
|
|
|
|
|
|
|
|
|
|
Deferred purchase price liabilities: |
|
|
|
|
|
|
|
Deferred purchase price liabilities |
4,318
|
|
|
—
|
|
|
—
|
|
|
4,318
|
|
TRA obligation |
4,537
|
|
|
—
|
|
|
—
|
|
|
4,537
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability |
1,150
|
|
|
1,150
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total liabilities |
$ |
25,267,925
|
|
|
$ |
1,150
|
|
|
$ |
—
|
|
|
$ |
25,266,775
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
Total Fair Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets |
|
|
|
|
|
|
|
Loans held for investment, subject to HMBS related obligations |
$ |
11,114,100 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
11,114,100 |
|
Loans held for investment, subject to nonrecourse debt: |
|
|
|
|
|
|
|
Reverse mortgage loans |
7,065,477 |
|
|
— |
|
|
— |
|
|
7,065,477 |
|
Commercial mortgage loans |
389,161 |
|
|
— |
|
|
— |
|
|
389,161 |
|
Loans held for investment: |
|
|
|
|
|
|
|
Reverse mortgage loans |
771,724 |
|
|
— |
|
|
— |
|
|
771,724 |
|
Commercial mortgage loans |
136,274 |
|
|
— |
|
|
— |
|
|
136,274 |
|
|
|
|
|
|
|
|
|
Loans held for sale: |
|
|
|
|
|
|
|
Residential mortgage loans |
12,123 |
|
|
— |
|
|
12,123 |
|
|
— |
|
Commercial mortgage loans |
161,861 |
|
|
— |
|
|
— |
|
|
161,861 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MSR |
95,096 |
|
|
— |
|
|
— |
|
|
95,096 |
|
Derivative assets: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LPCs, forward MBS, and TBAs |
907 |
|
|
— |
|
|
907 |
|
|
— |
|
Interest rate swaps and futures contracts |
771 |
|
|
771 |
|
|
— |
|
|
— |
|
Other assets: |
|
|
|
|
|
|
|
Purchase commitments - reverse mortgage loans |
9,356 |
|
|
— |
|
|
— |
|
|
9,356 |
|
Retained bonds |
46,439 |
|
|
— |
|
|
— |
|
|
46,439 |
|
Total assets |
$ |
19,803,289 |
|
|
$ |
771 |
|
|
$ |
13,030 |
|
|
$ |
19,789,488 |
|
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
HMBS related obligations |
$ |
10,996,755 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
10,996,755 |
|
Nonrecourse debt: |
|
|
|
|
|
|
|
Nonrecourse debt in consolidated VIE trusts |
7,175,857 |
|
|
— |
|
|
— |
|
|
7,175,857 |
|
Nonrecourse commercial loan financing liability |
106,758 |
|
|
— |
|
|
— |
|
|
106,758 |
|
Nonrecourse MSR financing liability |
60,562 |
|
|
— |
|
|
— |
|
|
60,562 |
|
Deferred purchase price liabilities: |
|
|
|
|
|
|
|
Deferred purchase price liabilities |
137 |
|
|
— |
|
|
— |
|
|
137 |
|
TRA obligation |
3,781 |
|
|
— |
|
|
— |
|
|
3,781 |
|
Derivative liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swaps and futures contracts |
385 |
|
|
385 |
|
|
— |
|
|
— |
|
Warrant liability |
1,117 |
|
|
1,117 |
|
|
— |
|
|
— |
|
Total liabilities |
$ |
18,345,352 |
|
|
$ |
1,502 |
|
|
$ |
— |
|
|
$ |
18,343,850 |
|
Assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3, in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
Year ended December 31, 2023 |
Loans held for investment |
|
Loans held for investment, subject to nonrecourse debt |
|
Loans held for sale |
|
|
|
MSR |
|
Retained bonds |
|
Purchase commitments |
|
|
|
|
Beginning balance |
$ |
12,022,098
|
|
|
$ |
7,454,638
|
|
|
$ |
161,861
|
|
|
|
|
$ |
95,096
|
|
|
$ |
46,439
|
|
|
$ |
9,356
|
|
|
|
|
|
Total gain (loss) included in earnings |
1,003,208
|
|
|
506,993
|
|
|
(2,253) |
|
|
|
|
(2,582) |
|
|
847
|
|
|
—
|
|
|
|
|
|
Purchases, settlements, and transfers: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases and additions |
8,640,881
|
|
|
76,031
|
|
|
40,468
|
|
|
|
|
405
|
|
|
—
|
|
|
—
|
|
|
|
|
|
Sales and settlements |
(1,927,773) |
|
|
(1,349,682) |
|
|
(218,238) |
|
|
|
|
(86,483) |
|
|
(2,989) |
|
|
(9,356) |
|
|
|
|
|
Transfers in (out) between categories |
(1,614,423) |
|
|
1,584,413
|
|
|
18,162
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
Ending balance |
$ |
18,123,991
|
|
|
$ |
8,272,393
|
|
|
$ |
—
|
|
|
|
|
$ |
6,436
|
|
|
$ |
44,297
|
|
|
$ |
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
Year ended December 31, 2023 |
HMBS related obligations |
|
|
|
|
|
|
|
Nonrecourse debt in consolidated VIE trusts and reverse loan financing liability |
|
Nonrecourse commercial loan financing liability |
|
Nonrecourse MSR financing liability |
|
Deferred purchase price liabilities |
|
TRA obligation |
|
|
Beginning balance |
$ |
(10,996,755) |
|
|
|
|
|
|
|
|
$ |
(7,175,857) |
|
|
$ |
(106,758) |
|
|
$ |
(60,562) |
|
|
$ |
(137) |
|
|
$ |
(3,781) |
|
|
|
Total gain (loss) included in earnings |
(785,928) |
|
|
|
|
|
|
|
|
(431,248) |
|
|
860
|
|
|
748
|
|
|
69
|
|
|
(756) |
|
|
|
Purchases, settlements, and transfers: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases and additions |
(7,495,167) |
|
|
|
|
|
|
|
|
(1,701,349) |
|
|
(27,565) |
|
|
—
|
|
|
(4,385) |
|
|
—
|
|
|
|
Settlements |
1,924,130
|
|
|
|
|
|
|
|
|
1,431,522
|
|
|
106,195
|
|
|
59,814
|
|
|
135
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance |
$ |
(17,353,720) |
|
|
|
|
|
|
|
|
$ |
(7,876,932) |
|
|
$ |
(27,268) |
|
|
$ |
—
|
|
|
$ |
(4,318) |
|
|
$ |
(4,537) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
Year ended December 31, 2022 |
Loans held for investment |
|
Loans held for investment, subject to nonrecourse debt |
|
Loans held for sale |
|
|
|
MSR |
|
Retained bonds |
|
Purchase commitments |
|
Investments |
Beginning balance |
$ |
11,587,382 |
|
|
$ |
6,218,194 |
|
|
$ |
149,426 |
|
|
|
|
$ |
427,942 |
|
|
$ |
55,614 |
|
|
$ |
— |
|
|
$ |
6,000 |
|
Total gain (loss) included in earnings |
190,714 |
|
|
(744,123) |
|
|
(15,213) |
|
|
|
|
22,989 |
|
|
(8,668) |
|
|
9,356 |
|
|
(6,000) |
|
Purchases, settlements, and transfers: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases and additions |
6,165,003 |
|
|
117,010 |
|
|
1,119,578 |
|
|
|
|
122,362 |
|
|
— |
|
|
— |
|
|
— |
|
Sales and settlements |
(2,178,245) |
|
|
(1,847,648) |
|
|
(1,103,492) |
|
|
|
|
(478,197) |
|
|
(507) |
|
|
— |
|
|
— |
|
Transfers in (out) between categories |
(3,742,756) |
|
|
3,711,205 |
|
|
11,562 |
|
|
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Ending balance |
$ |
12,022,098 |
|
|
$ |
7,454,638 |
|
|
$ |
161,861 |
|
|
|
|
$ |
95,096 |
|
|
$ |
46,439 |
|
|
$ |
9,356 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities |
Year ended December 31, 2022 |
HMBS related obligations |
|
|
|
|
|
|
|
Nonrecourse debt in consolidated VIE trusts |
|
Nonrecourse commercial loan financing liability |
|
Nonrecourse MSR financing liability |
|
|
|
TRA obligation |
Beginning balance |
$ |
(10,422,358) |
|
|
|
|
|
|
|
|
$ |
(5,857,069) |
|
|
$ |
(111,738) |
|
|
$ |
(142,435) |
|
|
|
|
$ |
(29,380) |
|
Total gain (loss) included in earnings |
(29,015) |
|
|
|
|
|
|
|
|
316,963 |
|
|
2,527 |
|
|
(8,162) |
|
|
|
|
25,599 |
|
Purchases, settlements, and transfers: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchases and additions |
(2,870,650) |
|
|
|
|
|
|
|
|
(3,202,519) |
|
|
(205,746) |
|
|
(14,196) |
|
|
|
|
— |
|
Settlements |
2,325,268 |
|
|
|
|
|
|
|
|
1,566,768 |
|
|
208,199 |
|
|
104,231 |
|
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance |
$ |
(10,996,755) |
|
|
|
|
|
|
|
|
$ |
(7,175,857) |
|
|
$ |
(106,758) |
|
|
$ |
(60,562) |
|
|
|
|
$ |
(3,781) |
|
Fair Value Option
The Company has elected to measure its loans held for investment, loans held for sale, HMBS related obligations, nonrecourse debt, and purchase and sale commitments at fair value under the fair value option. The Company elected to apply the provisions of the fair value option to these assets and liabilities in order to align financial reporting presentation with the Company’s operational and risk management strategies. Presented in the tables below are the fair value and UPB, at December 31, 2023 and December 31, 2022, of financial assets and liabilities for which the Company has elected the fair value option (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
Estimated Fair Value |
|
Unpaid Principal Balance |
Assets at fair value under the fair value option |
|
|
|
|
Loans held for investment, subject to HMBS related obligations |
|
$ |
17,548,763
|
|
|
$ |
16,875,437
|
|
Loans held for investment, subject to nonrecourse debt: |
|
|
|
|
Reverse mortgage loans |
|
8,138,403
|
|
|
8,257,750
|
|
Commercial mortgage loans |
|
133,990
|
|
|
136,622
|
|
Loans held for investment: |
|
|
|
|
Reverse mortgage loans |
|
574,271
|
|
|
558,577
|
|
Commercial mortgage loans |
|
957
|
|
|
1,044
|
|
Loans held for sale: |
|
|
|
|
Residential mortgage loans |
|
4,246
|
|
|
9,247
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities at fair value under the fair value option |
|
|
|
|
HMBS related obligations |
|
17,353,720
|
|
|
16,875,437
|
|
Nonrecourse debt: |
|
|
|
|
Nonrecourse debt in consolidated VIE trusts and reverse loan financing liability |
|
7,876,932
|
|
|
8,429,135
|
|
Nonrecourse commercial loan financing liability |
|
27,268
|
|
|
26,661
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2022 |
|
Estimated Fair Value |
|
Unpaid Principal Balance |
Assets at fair value under the fair value option |
|
|
|
|
Loans held for investment, subject to HMBS related obligations |
|
$ |
11,114,100 |
|
|
$ |
10,719,000 |
|
Loans held for investment, subject to nonrecourse debt: |
|
|
|
|
Reverse mortgage loans |
|
7,065,477 |
|
|
7,240,125 |
|
Commercial mortgage loans |
|
389,161 |
|
|
405,970 |
|
Loans held for investment: |
|
|
|
|
Reverse mortgage loans |
|
771,724 |
|
|
724,800 |
|
Commercial mortgage loans |
|
136,274 |
|
|
143,373 |
|
Loans held for sale: |
|
|
|
|
Residential mortgage loans |
|
12,123 |
|
|
15,529 |
|
Commercial mortgage loans |
|
161,861 |
|
|
173,112 |
|
Other assets: |
|
|
|
|
Purchase commitments - reverse mortgage loans |
|
9,356 |
|
|
9,356 |
|
Liabilities at fair value under the fair value option |
|
|
|
|
HMBS related obligations |
|
10,996,755 |
|
|
10,719,000 |
|
Nonrecourse debt: |
|
|
|
|
Nonrecourse debt in consolidated VIE trusts |
|
7,175,857 |
|
|
7,819,992 |
|
Nonrecourse commercial loan financing liability |
|
106,758 |
|
|
105,291 |
|
Nonrecourse MSR financing liability |
|
60,562 |
|
|
60,562 |
|
Net fair value gains on loans and related obligations
Provided in the table below is a summary of the components of net fair value gains on loans and related obligations (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2023 |
|
For the year ended December 31, 2022 |
Net origination gains |
|
|
|
|
$ |
121,646
|
|
|
$ |
283,808 |
|
Interest income on mortgage loans |
|
|
|
|
1,617,954
|
|
|
890,857 |
|
Interest expense on HMBS and nonrecourse obligations |
|
|
|
|
(1,273,159) |
|
|
(600,689) |
|
Servicing related income, net(1)
|
|
|
|
|
25,583
|
|
|
11,599 |
|
Fair value changes from model amortization(2)
|
|
|
|
|
(228,391) |
|
|
(127,576) |
|
Net fair value gains from portfolio activity |
|
|
|
|
141,987
|
|
|
174,191 |
|
Net fair value gains (losses) from changes in market inputs or model assumptions |
|
|
|
|
58,696
|
|
|
(368,510) |
|
Net fair value gains on loans and related obligations |
|
|
|
|
$ |
322,329
|
|
|
$ |
89,489 |
|
(1) Servicing related income, net, is comprised of premiums realized on the securitization of reverse mortgage tails and miscellaneous contractual servicing fees, net of guarantee fees paid.
(2) Fair value changes from portfolio runoff and realization of modeled income and expenses.
As the cash flows on the underlying mortgage loans will be utilized to settle the outstanding obligations, the Company’s own credit risk would not impact the fair value on the outstanding HMBS related obligations and nonrecourse debt.
Fair Value of Other Financial Instruments
As of December 31, 2023 and December 31, 2022, all financial instruments were either recorded at fair value or the carrying value approximated fair value with the exception of notes payable, net. Notes payable, net, includes our senior unsecured high-yield debt and related-party credit line recorded at the carrying value of $410.9 million and $399.4 million as of December 31, 2023 and December 31, 2022, respectively, and have a fair value of
$345.6 million and $231.9 million as of December 31, 2023 and December 31, 2022, respectively. The fair value for notes payable, net, was determined using quoted market prices adjusted for accrued interest, which is considered to be a Level 2 input. For other financial instruments that were not recorded at fair value, such as cash and cash equivalents including restricted cash, promissory notes receivable, and other financing lines of credit, the carrying value approximates fair value due to the short-term nature of such instruments. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 3 inputs, with the exception of cash and cash equivalents, including restricted cash, which are Level 1 inputs.
|